{"url_path":"/sec/antx/8-k/2026-06-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1880438/0001193125-26-257430-index.html","accession_number":"0001193125-26-257430","cik":"0001880438","ticker":"ANTX","issuer_name":"AN2 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1880438/0001193125-26-257430-index.html","primary_entity_key":"0001880438","primary_entity_name":"AN2 Therapeutics, Inc."},"word_count":83,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n \n\nExhibit No.\n  \n\nDescription\n\n99.1\n  \n[Press release of AN2 Therapeutics, Inc. dated June 4, 2026.](d247428dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDated: June 4, 2026\n \n\n \nAN2 Therapeutics, Inc.\n\n \n\n \nBy:\n \n\n/s/ Joshua Eizen\n\n \n\n \n\n \nJoshua Eizen\n\n \n\n \n\n \nChief Legal Officer and Chief Operating Officer"}